Last reviewed by Dr. Dharmender Malik on 14 May 2026 · this article reflects the published primary literature and current clinical practice at FMRI Gurugram.
Introduction
Cost is one of the first questions patients and families ask about Lu-177 PSMA-617 (sold in regulated Western markets as Pluvicto) therapy — and one of the most poorly answered online. The pricing landscape is genuinely complex: it varies by isotope source, the number of cycles delivered, whether dosimetry imaging is bundled, the centre's overhead structure, and the inclusion of supporting workup such as Ga-68 PSMA PET-CT eligibility scans. This article sets out, with sourced primary literature where available, what Lu-177 PSMA therapy realistically costs in India — what the per-cycle bundle should include, how it compares to international pricing, and what a patient should ask for in writing before agreeing to treatment.
What goes into a Lu-177 PSMA cost bundle
AI Overview · short answer
Lu-177 PSMA-617 therapy cost in India varies meaningfully by treating centre, isotope source (domestic BRIT supply versus international suppliers), and the bundle of services included. International list pricing for branded Pluvicto in the United States has been reported at approximately USD 42,500 per cycle pre-discount[1]. Indian per-cycle costs are meaningfully lower, but the precise figure must be obtained from the treating centre as an itemised quote that covers isotope, dose, professional fees, imaging, hospital admission, and follow-up[2]. Any comparison should be bundle-to-bundle, not isotope-cost alone.
A Lu-177 PSMA therapy quote in India should never be a single line item. A clinically sound, itemised per-cycle quote covers the following components[2]:
- The radioligand itself — Lu-177 PSMA-617 at the prescribed activity (typically 7.4 GBq / 200 mCi per cycle, mirroring the VISION trial protocol).
- Eligibility imaging — Ga-68 PSMA PET-CT before cycle 1 to confirm PSMA expression and disease burden.
- Dosimetry imaging — post-administration SPECT/CT (typically next-day) to confirm tumour uptake and assess organ-at-risk dose. Some centres also do mid-treatment Ga-68 PSMA PET re-staging.
- Hospital admission and nursing care — most Indian centres admit patients for a short stay (24–72 hours) per cycle for radiation containment, monitoring, and discharge counselling.
- Professional fees — nuclear medicine physician, medical physicist, and radiation safety officer time across consent, administration, and follow-up.
- Pre-cycle and post-cycle workup — kidney function, marrow counts, liver function, PSA trajectory.
- Supportive medications — anti-emetics, hydration, occasional bone-pain management. Salivary-gland cooling protocols where used.
A quote that only states the price of the isotope is not a quote for treatment — it is a quote for a substance. The actual cost of therapy is the bundle.
Why isotope source affects the cost
Indian centres source Lu-177 from two broad channels, and the per-cycle cost varies accordingly[3]:
| Source | Description | Typical cost characteristic |
|---|
| BRIT (BARC subsidiary, India) | Domestic supply of Lu-177 from the Board of Radiation and Isotope Technology, both carrier-added and no-carrier-added grades | Generally lower isotope cost; widely used at AIIMS, Tata Memorial, and other Indian programmes |
| International commercial supply | IDB Holland, ITM Germany, and others — Lu-177 imported under DCGI permissions | Higher isotope cost due to import, logistics, and licensing |
| Pluvicto (Novartis branded) | Pre-formulated Lu-177 PSMA-617 product approved in the US and EU | Highest cost; branded product list pricing in the US reported around USD 42,500 per cycle pre-discount[1] |
Indian centres delivering non-branded Lu-177 PSMA therapy use Lu-177 (BRIT or imported) combined with PSMA-617 precursor, compounded in-house or at partner radiopharmacy facilities under regulatory oversight. The clinical outcomes from non-branded Indian preparations have been documented in peer-reviewed publications and are broadly consistent with branded-product outcomes in international cohorts[4][5].
International cost — for context only
Lu-177 PSMA therapy is delivered in the United States, European Union, the United Kingdom, Australia, and a growing list of countries. The list price for Pluvicto in the United States has been reported at approximately USD 42,500 per cycle pre-discount, with patients typically receiving up to six cycles in the VISION protocol — implying a treatment-course cost approaching USD 255,000 before insurance and discounts are applied[1]. Reported out-of-pocket costs in international markets vary very substantially with insurance coverage, hospital negotiation, manufacturer assistance programmes, and prior-authorisation outcomes.
European pricing for branded Pluvicto has been the subject of negotiation in several national health systems[6]. The point relevant to Indian patients is that international list pricing reflects a particular regulatory and reimbursement context that does not directly translate to Indian self-pay or insurance pathways. Indian costs are meaningfully lower — but the right comparison is bundle-to-bundle, not headline-to-headline.
Cycles, treatment course, and total expenditure
The VISION trial protocol delivered up to six cycles of 7.4 GBq Lu-177 PSMA-617 at 6-week intervals[7]. Indian protocols generally mirror this framework, with treatment course determined by response, tolerability, and disease trajectory:
- Most patients receive 4–6 cycles depending on PSA response, imaging response, and toxicity profile[4].
- Some patients receive fewer cycles — if early disease progression is documented or unacceptable toxicity (most commonly cytopenia or xerostomia) is observed.
- Some patients receive additional cycles beyond six if continued response is documented and tolerability is acceptable.
When evaluating total expenditure, patients should plan for the bundle cost multiplied by an expected 4–6 cycles, plus the costs of inter-cycle workup (PSA trends, imaging re-staging at intervals), travel and accommodation costs if applicable, and the costs of any follow-up therapy after the Lu-177 PSMA course is complete.
What an itemised quote should include
A clinically appropriate, transparent Indian quote for Lu-177 PSMA therapy should be provided in writing and include — at minimum — the following line items[8]:
- Isotope (Lu-177) source and prescribed activity per cycle (in GBq and mCi).
- PSMA-617 precursor source.
- Ga-68 PSMA PET-CT eligibility scan cost (per scan).
- Post-administration SPECT/CT imaging cost (per scan).
- Hospital admission charges (room, nursing, radiation safety surcharge).
- Professional fees — nuclear medicine physician, medical physicist, supporting consultants.
- Pre-cycle workup — biochemistry, PSA.
- Supportive medications and consumables.
- Whether the quote is per cycle or course; if a course, how many cycles are included and how additional cycles are priced.
- Cancellation, partial-completion, and refund terms.
A reputable centre will provide this in writing as part of consent — not verbally and not only at the time of billing.
What the quote may not include
Most quotes — even good ones — exclude the following, which patients should plan for separately:
- Travel and accommodation for the patient and one caregiver across multiple cycles.
- Inter-cycle re-staging imaging if not bundled into the cycle cost (some protocols re-stage at the 3rd or 4th cycle).
- Treatment of intercurrent illness — infections, dehydration, separately treated bone-pain events.
- Concurrent systemic therapy — ARPI continuation, bone-targeted agents, hormone therapy.
- Specialist consultations with urology, medical oncology, palliative care.
- Indirect costs — caregiver time off work, lost wages, ancillary travel costs.
Insurance and payment pathways in India
Insurance coverage for Lu-177 PSMA therapy in India varies meaningfully by policy, insurer, and treating centre relationship[9]:
- Indian private health insurance — some Indian policies cover advanced oncology including radioligand therapy. Coverage limits, pre-authorisation requirements, and reimbursement timelines should be confirmed with the insurer before therapy begins.
- Cashless networks — some Indian centres have cashless arrangements with specific insurers; others operate on reimbursement basis with the patient paying upfront and claiming.
- International insurance — for international patients, coverage depends on the home-country insurer's willingness to cover overseas radioligand therapy, the centre's billing relationship with that insurer, and documentation requirements.
- Self-pay — many patients pay self-pay with itemised receipts that can be submitted to insurance, employer reimbursement schemes, or charitable assistance programmes.
- Manufacturer or charitable assistance — some patient-assistance programmes have been documented for international patients, though access and eligibility vary considerably.
What to ask the treating centre before you commit
Before agreeing to begin a course of Lu-177 PSMA therapy at any Indian centre, patients and families should ask the following — and receive answers in writing[10]:
- Is the centre AERB-licensed for therapeutic radionuclide administration? Can the current licence be verified?
- What is the isotope source (BRIT, ITM, IDB Holland, or branded Pluvicto)?
- Who handles compounding and quality control, and under what licensure?
- What is the prescribed activity per cycle, and what is the total prescribed course?
- What's bundled in the per-cycle quote, and what's billed separately?
- Are Ga-68 PSMA PET-CT and post-administration SPECT/CT included?
- What is the protocol for response assessment between cycles?
- Who is the responsible nuclear medicine physician, and what is their PRRT/PSMA case experience?
- Is there integrated urology and medical oncology review of the case?
- What is the centre's institutional experience with PSMA radioligand therapy (case numbers, outcomes published, if any)?
Cost transparency as a quality marker
An Indian centre that is willing to provide a detailed, itemised written quote — covering all bundle and non-bundle components — is generally a centre that is also serious about clinical governance, informed consent, and post-treatment shared care. The two qualities tend to travel together. Conversely, a quote that resists itemisation, depends on opaque language, or shifts costs onto unexpected line items at the time of billing is a warning sign that should weigh heavily in centre selection.
The same logic applies to international patients: the centre's willingness to issue a transparent written quote before travel — with explicit handling of currency, taxes, and post-treatment shared-care documentation — is part of the quality picture, not separate from it.
The bottom line
- Lu-177 PSMA-617 therapy cost in India must be quoted as an itemised bundle, not a single line for isotope alone[2].
- Isotope source (BRIT domestic, international supply, or branded Pluvicto) is the largest single driver of per-cycle cost variation[3].
- International list pricing (around USD 42,500 per cycle for branded Pluvicto in the US, pre-discount) reflects a different regulatory and reimbursement context and does not translate directly to Indian self-pay[1].
- A clinically sound Indian quote should be in writing and include isotope, prescribed activity, professional fees, imaging, admission, supportive medications, and clear handling of additional-cycle pricing[8].
- Excluded costs (travel, intercurrent illness, concurrent therapy, indirect costs) should be planned for separately.
- Insurance and payment pathways vary; patients should confirm coverage, pre-authorisation, and reimbursement timelines with their insurer before therapy begins.
- Centre transparency on cost is itself a quality marker correlated with clinical governance, informed consent, and shared care quality.
Important
This article is general information about Lu-177 PSMA therapy costs in India. Specific per-cycle and per-course costs vary by centre and by patient-specific factors. Itemised written quotes should be obtained directly from treating centres as part of pre-treatment planning. This article does not constitute financial or insurance advice.
"Cost should be discussed with the same clinical seriousness as eligibility, dosimetry, and tolerability. A centre that gives an itemised written quote — and stays accountable to it — is also more likely to give honest informed consent, sound dosimetry, and proper post-treatment shared care. Cost transparency and clinical rigor are correlated, not separate, qualities."
Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI
Cost transparency · Lu-177 PSMA at FMRI
For Lu-177 PSMA therapy at FMRI Gurugram, our nuclear medicine team can review eligibility (Ga-68 PSMA PET-CT, prior treatment record, recent biochemistry) and provide a fully itemised written quote covering isotope, professional fees, imaging, admission, and follow-up — before any commitment is made.
Request an itemised quote · WhatsApp +91 8800 988936
For patients & referring clinicians
Frequently asked questions
Q01
How much does Lu-177 PSMA therapy cost in India?
Lu-177 PSMA-617 therapy cost in India varies meaningfully by isotope source (domestic BRIT supply versus international supply versus branded Pluvicto), treating centre, and the bundle of services included. Specific per-cycle costs should be obtained from the treating centre as a written itemised quote covering isotope, professional fees, imaging, admission, and follow-up. Cost in India is generally meaningfully lower than equivalent therapy in the United States, where branded Pluvicto list pricing has been reported at approximately USD 42,500 per cycle pre-discount [1].
Q02
Why does Lu-177 PSMA cost vary between Indian centres?
Cost varies across Indian centres for several reasons: the isotope source (domestic BRIT versus imported), whether the centre uses branded Pluvicto or compounded Lu-177 PSMA-617, the prescribed activity per cycle, what is bundled in the per-cycle quote (imaging, hospital admission, professional fees), and the centre's overhead structure. Patients should compare itemised written quotes, not headline figures [2][3].
Q03
How many cycles does a full course typically involve?
The VISION trial protocol delivered up to six cycles of 7.4 GBq (200 mCi) Lu-177 PSMA-617 at 6-week intervals [7]. Indian protocols generally mirror this framework — most patients receive 4–6 cycles depending on PSA response, imaging response, tolerability, and disease trajectory. Some patients receive fewer cycles if disease progression or unacceptable toxicity occurs; some receive additional cycles if continued response is documented.
Q04
Is the Ga-68 PSMA PET-CT scan included in the cost?
It depends on the centre. Some centres bundle the eligibility Ga-68 PSMA PET-CT scan into the cycle 1 quote; others bill it separately. Patients should clarify in writing whether the eligibility scan and any inter-cycle response assessment scans (typically performed at the 3rd or 4th cycle) are bundled or billed separately [2].
Q05
What's the difference between branded Pluvicto and compounded Lu-177 PSMA-617?
Branded Pluvicto is the Novartis-marketed, pre-formulated Lu-177 PSMA-617 product approved by the FDA (2022) and EMA. Compounded Lu-177 PSMA-617 refers to in-house or partner-radiopharmacy formulations using Lu-177 (from BRIT or international suppliers) combined with PSMA-617 precursor, under DCGI permissions and AERB licensure. Indian published cohorts using compounded preparations report PSA response and survival outcomes broadly consistent with international VISION trial data [4][5]. Cost differs substantially.
Q06
Does Indian health insurance cover Lu-177 PSMA therapy?
Coverage varies by policy and insurer. Some Indian private health insurance policies cover advanced oncology including radioligand therapy, subject to coverage limits, pre-authorisation, and policy terms. Patients should confirm coverage with their insurer before therapy begins. Some centres have cashless arrangements with specific insurers; others operate on reimbursement basis [9].
Q07
What about international insurance for Indian Lu-177 PSMA therapy?
For international patients, coverage depends on the home-country insurer's willingness to cover overseas radioligand therapy, the Indian centre's billing relationship with that insurer, and documentation requirements. Some international policies cover overseas care; others do not. Specific coverage arrangements should be confirmed directly with the insurer and the treating centre [9].
Q08
Are there hidden costs patients should expect?
Most itemised quotes do not include: travel and accommodation, inter-cycle re-staging imaging (if not bundled), treatment of intercurrent illness during therapy, concurrent systemic therapy (ARPI, bone agents), specialist consultations, and indirect costs (caregiver time, lost wages). Patients should plan for these separately [10].
Q09
Are payment plans or financial assistance available?
Some Indian centres offer phased payment arrangements where cycles are billed individually rather than as a course in advance. Some charitable assistance programmes and manufacturer access programmes have been documented but access and eligibility vary considerably and should be confirmed directly. Patients should not assume retrospective price reductions are available once therapy has begun [9].
Q10
Why might a very low quote be a warning sign?
A quote substantially below typical Indian centre pricing may reflect omitted services (no eligibility Ga-68 PSMA PET, no post-administration SPECT/CT, no integrated multidisciplinary review), sub-optimal isotope grade or activity, or quality-of-governance shortcuts. The clinically right comparison is bundle-to-bundle: what's the centre's AERB licensure, who is the responsible physician, what is the published experience, and what is the protocol for response assessment and shared care? Cost cannot be assessed independent of these [10].
Q11
How should I compare quotes across centres?
Request written itemised quotes from each centre. For each, confirm: isotope source and prescribed activity, what's bundled, what's billed separately, eligibility imaging cost, post-administration imaging cost, professional fees, hospital admission charges, and additional-cycle pricing. Then weigh against centre quality factors: AERB licensure, qualified personnel, published experience, integrated multidisciplinary review, and quality of informed consent. Pure cost comparison without quality weighting is incomplete.
Q12
How do I get an itemised quote for Lu-177 PSMA therapy at FMRI?
For Lu-177 PSMA therapy at FMRI Gurugram, our nuclear medicine team can review eligibility (recent Ga-68 PSMA PET-CT, prior treatment record, recent biochemistry) and provide a fully itemised written quote covering isotope, professional fees, imaging, admission, and follow-up, before any commitment is made. WhatsApp +91 8800 988936 to begin a confidential review.
Citations & references
All clinical numbers above are sourced from the primary literature listed below. Every reference links to the open journal page or the regulatory archive — open in a new tab to verify.
[1] U.S. Food and Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer (March 23, 2022). FDA News Release.
View source ↗[2] European Association of Nuclear Medicine. EANM procedure guidelines for radionuclide therapy with
177Lu-labelled PSMA-ligands.
Eur J Nucl Med Mol Imaging. 2019;46(12):2536-2544.
View source ↗[3] Department of Atomic Energy, Government of India. Board of Radiation and Isotope Technology (BRIT) — Annual Reports on Medical Isotope Production.
View source ↗[4] Yadav MP, Ballal S, Tripathi M, et al.
177Lu-DKFZ-PSMA-617 therapy in metastatic castration-resistant prostate cancer: safety, efficacy, and quality of life.
Eur J Nucl Med Mol Imaging. 2017;44(1):81-91.
View source ↗[5] Basu S, Parghane RV, Banerjee S, et al. Long-term outcome of
177Lu-PSMA-617 therapy in mCRPC: Indian institutional experience.
Clin Nucl Med. 2021;46(10):820-826.
View source ↗[6] Hennrich U, Eder M.
177Lu-PSMA-617 (Pluvicto): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.
Pharmaceuticals (Basel). 2022;15(10):1292.
View source ↗[7] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION trial).
N Engl J Med. 2021;385(12):1091-1103.
View source ↗[8] Atomic Energy Regulatory Board (Government of India). Safety Code for Nuclear Medicine Facilities. AERB/RF-MED/SC-2 (Rev. 2).
View source ↗[9] Bhatnagar V, Pandey AK, Singh H, et al. Health Insurance and Out-of-Pocket Costs for Cancer Treatment in India: A Review.
Indian J Med Res. 2020;152(4):340-348.
View source ↗[10] Indian College of Nuclear Medicine. Guidelines for accreditation and training of nuclear medicine therapy facilities in India.
View source ↗[11] Hofman MS, Violet J, Hicks RJ, et al. [
177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial).
Lancet Oncol. 2018;19(6):825-833.
View source ↗[12] Sahoo RK, Yadav MP, Ballal S, et al. Health-related quality of life outcomes after Lu-177 PSMA therapy in mCRPC: Indian cohort.
Asia Ocean J Nucl Med Biol. 2022.
View source ↗[13] Iravani A, Violet J, Azad A, et al. Lutetium-177 PSMA therapy: practical aspects, dosimetry, and outcomes.
Theranostics. 2020;10(20):8854-8866.
View source ↗[14] Mittal BR, Kumar A, Sood A, et al. Practice of Nuclear Medicine Therapy in India: Audit of a Tertiary Care Centre.
Indian J Nucl Med. 2020;35(2):126-131.
View source ↗[15] Hofman MS, Emmett L, Sandhu S, et al. [
177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP trial).
Lancet. 2021;397(10276):797-804.
View source ↗[16] Roviello G, Catalano M, Ravelli A, et al. Cost-effectiveness assessment of Lu-177 PSMA-617 in metastatic prostate cancer.
Cancers (Basel). 2023;15(13):3290.
View source ↗[17] Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for PRRT.
Pharmaceuticals (Basel). 2019;12(3):114.
View source ↗[18] Calais J, Czernin J, Cao M, et al.
68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy.
J Nucl Med. 2018;59(4):576-585.
View source ↗[19] Singh S, Tang LH, Brand R, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. National Comprehensive Cancer Network.
View source ↗[20] European Association of Urology. EAU Guidelines on Prostate Cancer. 2024 Update.
View source ↗[21] Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted alpha-therapy of mCRPC with
225Ac-PSMA-617: dosimetry and toxicity.
J Nucl Med. 2017;58(10):1624-1631.
View source ↗[22] Sathekge M, Bruchertseifer F, Knoesen O, et al.
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer.
Eur J Nucl Med Mol Imaging. 2019;46(1):129-138.
View source ↗[23] Heck MM, Tauber R, Schwaiger S, et al. Treatment outcome and toxicity for
177Lu-PSMA-I&T in mCRPC.
Eur Urol. 2019;75(6):920-926.
View source ↗[24] Rasul S, Hartenbach M, Wadsak W, et al. Clinical outcome with [
177Lu]Lu-PSMA-I&T.
Eur J Nucl Med Mol Imaging. 2020;47(13):3107-3116.
View source ↗[25] Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of overall and disease-free survival in mCRPC receiving
225Ac-PSMA-617.
J Nucl Med. 2020;61(1):62-69.
View source ↗[26] Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer (LATITUDE).
N Engl J Med. 2017;377(4):352-360.
View source ↗[27] James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE).
N Engl J Med. 2017;377(4):338-351.
View source ↗[28] Yadav MP, Ballal S, Sahoo RK, et al.
225Ac-PSMA-617 in mCRPC after failure of Lu-177 PSMA-617.
Eur J Nucl Med Mol Imaging. 2024.
View source ↗[29] Tagawa ST, Vallabhajosula S, Christos PJ, et al. Phase I/II study of fractionated dose
177Lu-J591.
Cancer. 2019;125(15):2561-2569.
View source ↗[30] Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy.
Bioconjug Chem. 2011;22(10):1879-1903.
View source ↗
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York
Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.